Group 1 - On January 14, 2026, China Asset Management announced dividend distributions for 17 funds, including active equity, bonds, and passive index products, with the Jiashi Theme Selection fund having distributed over 10 billion yuan since its inception [1] - The China Europe Fund announced a proportionate allocation for its small-cap growth mixed fund, which exceeded its asset limit of 2 billion yuan, confirming a ratio of 47.84% for effective subscription applications as of January 12, 2026 [2] - Medical-themed funds have shown strong performance at the start of 2026, with several funds achieving returns significantly higher than their entire 2025 performance, such as the Galaxy Kang Le Mixed Fund with a 24% return in the first two weeks of the year [3] Group 2 - Public fund institutions have focused their research efforts on the technology sector, with 145 institutions participating in A-share company research, covering 154 stocks across 26 industries, with a total of 999 research instances [4] - The investment limit for non-direct channel subscriptions to the QDII fund managed by Pi Jinsong has been raised from 2,000 yuan to 20,000 yuan per day per account, reflecting a significant change in investment strategy [5] - On January 15, 2026, the three major indices showed mixed results, with the Shanghai Composite Index down 0.33% and the Shenzhen Component Index up 0.41%, while the total trading volume decreased by 1.04 trillion yuan compared to the previous trading day [6]

Group 1 - The core point of the article highlights the dramatic turnaround of the Wanjiacong ZHONGZHENG Hong Kong Stock Connect Innovative Drug ETF, which achieved a remarkable year-to-date return of 114.01%, ranking first among all funds in the market [1][3] - The ETF, established in September 2022, initially suffered a significant excess loss of 52%, indicating a poor performance compared to its benchmark [2][3] - The fund's cumulative return since inception is 79.94%, which lags behind its benchmark by over 52 percentage points, showcasing a substantial tracking error for a passively managed ETF [3][4] Group 2 - The tracking error stemmed from poor initial positioning during the fund's launch, coinciding with a bearish market environment, leading to missed opportunities during a subsequent market rebound [4][5][7] - The fund's management team failed to establish positions promptly, resulting in a net asset value that lagged behind the benchmark index by nearly 27 percentage points [7] - The eventual success of the fund was attributed more to favorable market conditions in the innovative drug sector rather than superior management skills, highlighting a reliance on market luck [7][8] Group 3 - The article reflects on the historical context of Wanjiacong's fund management, tracing back to its origins as a pioneer in index investing in China, which faced strategic setbacks over the years [8][9] - In recent years, the company has aggressively expanded its index fund offerings, launching 43 new products from 2023 to 2025, indicating a strategic shift towards prioritizing index business [10][12] - However, this rapid expansion has led to operational challenges, with nearly half of its index funds underperforming their benchmarks, suggesting systemic issues in investment processes and risk management [13][14] Group 4 - The performance of actively managed funds under Wanjiacong also reflects weaknesses, with some funds showing significant losses and failing to capitalize on market trends, indicating broader issues in research and investment capabilities [15][16] - The article emphasizes the need for the company to address the gap between its ambitious goals and operational realities to avoid repeating past mistakes in its investment strategy [20]